Abstract:Background: Accumulating evidence has highlighted the potential role of long non-coding RNAs (lncRNAs) in the biological behaviors of hepatocellular carcinoma (HCC). Here, we elucidated the function and possible molecular mechanisms of the effect of lncRNA-AGAP2-AS1 on the biological behaviors of HCC. Methods: EdU, Transwell and flow cytometry were used to determine proliferation, migration, invasion and apoptosis of HCC cells in vitro. The subcutaneous tumor model and lung metastasis mouse model in nude mice was established to detect tumor growth and metastasis of HCC in vivo. The direct binding of miR-16-5p to 3'UTR of ANXA11 was confirmed by luciferase reporter assay. The expression of AGAP2-AS1 and miR-16-5p in HCC specimens and cell lines were detected by real-time PCR. The correlation among AGAP2-AS1 and miR-16-5p were disclosed by a dual-luciferase reporter assay, RIP assay and biotin pull-down assay. Results: Here, we demonstrated that AGAP2-AS1 expression was up-regulated in HCC tissues and cell lines, especially in metastatic and recurrent cases. Gain- and loss-of-function experiments indicated that AGAP2-AS1 promoted cell proliferation, migration, invasion, EMT progression and inhibited apoptosis of HCC cells in vitro and in vivo. Further studies demonstrated that AGAP2-AS1 could function as a competing endogenous RNA (ceRNA) by sponging miR-16-5p in HCC cells. Functionally, gain- and loss-of-function studies showed that miR-16-5p promoted HCC progression and alteration of miR-16-5p abolished the promotive effects of AGAP2-AS1 on HCC cells. Moreover, ANXA11 was identified as direct downstream targets of miR-16-5p in HCC cells, and mediated the functional effects of miR-16-5p and AGAP2-AS1 in HCC, resulting in AKT signaling activation. Clinically, AGAP2-AS1 and miR-16-5p expression were markedly correlated with adverse clinical features and poor prognosis of HCC patients. We showed that hypoxia was responsible for the overexpression of AGAP2-AS1 in HCC. And the promoting effects of hypoxia on metastasis and EMT of HCC cells were reversed by AGAP2-AS1 knockdown. Conclusions: Taken together, this research supports the first evidence that AGAP2-AS1 plays an oncogenic role in HCC via AGAP2-AS1/miR-16-5p/ANXA11/AKT axis pathway and represents a promising therapeutic strategy for HCC patients.Funding Statement: This study was supported by grants from the National Natural Science Foundation of China (81572847, 81402039).Declaration of Interests: The authors declare that they have no competing interests.Ethics Approval Statement: The protocols for these animal experiments were approved by the Ethics Review Committee of Xi’an Jiaotong University.All procedures performed in studies involving human participants were in accordance with the ethical standards of the Research Ethics Committee of The First Affiliated Hospital of Xi’an Jiaotong University and with the 1964 Helsinki declaration and its later amendments. ALL written informed consent to participate in the study was obtained from HCC patients for samples to be collected from them

The Antisense Long Noncoding RNA AGAP2-AS1 Regulates Cell Proliferation and Metastasis in Epithelial Ovarian Cancer.

Oncogenic Roles and Mechanisms of Lncrna AGAP2-AS1 in Human Solid Tumors.

Long Non-Coding RNA SLC25A21-AS1 Inhibits the Development of Epithelial Ovarian Cancer by Specifically Inducing PTBP3 Degradation

Long Non-Coding RNA AGAP2-AS1: A Comprehensive Overview on Its Biological Functions and Clinical Significances in Human Cancers

Upregulated long non-coding RNA AGAP2-AS1 represses LATS2 and KLF2 expression through interacting with EZH2 and LSD1 in non-small-cell lung cancer cells

LncRNA HOXA‐AS2 promotes the progression of epithelial ovarian cancer via the regulation of miR‐372

Long Non-Coding RNA RHPN1-AS1 Promotes Tumorigenesis and Metastasis of Ovarian Cancer by Acting As a Cerna Against Mir-596 and Upregulating LETM1.

Long Non-Coding RNA AGAP2-AS1 Promotes Cell Proliferation and Invasion Through Regulating Mir-193A-3p/loxl4 Axis in Laryngeal Squamous Cell Carcinoma

Long Non-Coding RNA AOC4P Suppresses Epithelial Ovarian Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition

E2F1-regulated Long Non-Coding RNA RAD51-AS1 Promotes Cell Cycle Progression, Inhibits Apoptosis and Predicts Poor Prognosis in Epithelial Ovarian Cancer

Expression of long non-coding RNA NR2F2-AS1 in human epithelial ovarian cancer

Long non‐coding RNA AGAP2-AS1 promotes proliferation and metastasis in papillary thyroid cancer by miR-628-5p/KLF12 axis

MicroRNA-520g Promotes Epithelial Ovarian Cancer Progression and Chemoresistance Via DAPK2 Repression

Extracellular Vesicles Long Non-Coding RNA AGAP2-AS1 Contributes to Cervical Cancer Cell Proliferation Through Regulating the Mir-3064-5p/sirt1 Axis

lncRNA AGAP2-AS1 Facilitates Tumorigenesis and Ferroptosis Resistance through SLC7A11 by IGF2BP2 Pathway in Melanoma

Long Noncoding RNA TC0101441 Induces Epithelial–mesenchymal Transition in Epithelial Ovarian Cancer Metastasis by Downregulating KiSS1

Long Non-Coding RNA AGAP2-AS1, Functioning As a Competitive Endogenous RNA, Upregulates ANXA11 Expression by Sponging Mir-16-5p and Promotes Proliferation and Metastasis in Hepatocellular Carcinoma

Long Noncoding RNA LINC00673 Promotes the Proliferation and Metastasis of Epithelial Ovarian Cancer by Associating with Opioid Growth Factor Receptor.

Long Non-Coding RNA ZEB2-AS1 Expression is Associated with Disease Progression and Predicts Outcome in Gastric Cancer Patients.

TRPM2-AS promotes ovarian cancer cell proliferation and inhibits cell apoptosis by upregulating the nearby gene TRPM2 via miR-6764-5p

Long non-coding RNA NRSN2-AS1 promotes ovarian cancer progression through targeting PTK2/β-catenin pathway